Holen Sie sich die Stockscreener-App
9.37
6.02%
-0.60
Handel nachbörslich:
9.30
-0.07
-0.75%
Schlusskurs vom Vortag:
$9.97
Offen:
$9.75
24-Stunden-Volumen:
1.01M
Relative Volume:
0.68
Marktkapitalisierung:
$832.10M
Einnahmen:
$73.48M
Nettoeinkommen (Verlust:
$-108.30M
KGV:
-4.1644
EPS:
-2.25
Netto-Cashflow:
$-67.17M
1W Leistung:
-7.87%
1M Leistung:
+17.57%
6M Leistung:
+67.62%
1J Leistung:
+74.81%
1-Tages-Spanne:
$9.21
$9.935
1-Wochen-Bereich:
$9.21
$10.69
52-Wochen-Spanne:
$2.8262
$11.50
Personalis Inc Stock (PSNL) Company Profile
Firmenname
Personalis Inc
Sektor
Branche
Telefon
650-752-1300
Adresse
6600 DUMBARTON CIRCLE, FREMONT, CA
Vergleichen Sie PSNL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PSNL
Personalis Inc
|
9.37 | 885.38M | 73.48M | -108.30M | -67.17M | -2.25 |
|
TMO
Thermo Fisher Scientific Inc
|
578.61 | 222.48B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
218.89 | 155.25B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
670.46 | 54.04B | 4.17B | 1.03B | 940.22M | 12.61 |
|
IQV
Iqvia Holdings Inc
|
230.15 | 40.13B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
133.85 | 37.78B | 6.95B | 1.30B | 1.15B | 4.5696 |
Personalis Inc Stock (PSNL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2025-05-15 | Eingeleitet | Guggenheim | Buy |
| 2025-03-17 | Eingeleitet | Craig Hallum | Buy |
| 2023-02-06 | Hochstufung | Needham | Hold → Buy |
| 2022-01-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-11-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-03 | Herabstufung | Needham | Buy → Hold |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-09-20 | Bestätigt | Needham | Buy |
| 2021-05-06 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2021-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-11-12 | Bestätigt | Needham | Buy |
| 2020-11-06 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-10-19 | Eingeleitet | Citigroup | Buy |
| 2020-10-08 | Eingeleitet | BTIG Research | Buy |
| 2020-08-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-08-18 | Eingeleitet | Needham | Buy |
| 2019-09-26 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-07-15 | Eingeleitet | BofA/Merrill | Neutral |
| 2019-07-15 | Eingeleitet | Cowen | Outperform |
| 2019-07-15 | Eingeleitet | Morgan Stanley | Overweight |
| 2019-07-15 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Personalis Inc Aktie (PSNL) Neueste Nachrichten
Personalis, Inc. (PSNL) Stock Analysis: A 11.76% Potential Upside Amidst Revenue Challenges - DirectorsTalk Interviews
Wall Street Zen Upgrades Personalis (NASDAQ:PSNL) to Hold - Defense World
Is Personalis Inc.’s growth already priced inJuly 2025 Recap & Consistent Return Strategy Ideas - mfd.ru
Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference - BioSpace
Insider Selling: Personalis (NASDAQ:PSNL) CFO Sells $13,811.50 in Stock - Defense World
What 9 Analyst Ratings Have To Say About Personalis - Benzinga
Guggenheim Raises Price Target for Personalis (PSNL) to $13.00 | - GuruFocus
Gainers Report: Is Personalis Incs growth already priced inShare Buyback & Entry Point Strategy Guides - baoquankhu1.vn
Personalis (NASDAQ:PSNL) Sets New 12-Month High – Still a Buy? - Defense World
Hedge Fund Bets: Should you avoid Personalis Inc stock right nowEarnings Risk Summary & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Personalis, Inc. $PSNL Shares Purchased by AIGH Capital Management LLC - MarketBeat
Personalis (NASDAQ:PSNL) CFO Sells $13,811.50 in Stock - MarketBeat
Personalis CFO Tachibana sells $13,811 in shares By Investing.com - Investing.com Australia
Personalis CFO Tachibana sells $13,811 in shares - Investing.com
Personalis (NASDAQ:PSNL) Reaches New 12-Month HighWhat's Next? - MarketBeat
Personalis Sees Revised Reimbursement Rates for Cancer Tests - MSN
Personalis (NASDAQ:PSNL) Trading 14.8% HigherStill a Buy? - MarketBeat
Market Rankings: How does PLRX perform in inflationary periodsWeekly Stock Recap & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
How A New Price Target Is Shaping The Evolving Story For Personalis (PSNL) - Yahoo Finance
Winners Losers: Is Personalis Incs growth already priced inDollar Strength & Risk Controlled Daily Plans - baoquankhu1.vn
Personalis, Inc. (NASDAQ:PSNL) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Trading Action: Can Personalis Inc grow without external fundingJuly 2025 Volume & Weekly High Return Stock Forecasts - baoquankhu1.vn
Personalis, Inc. (NASDAQ:PSNL) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable - simplywall.st
Personalis (NASDAQ:PSNL) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
Personalis, Inc. (PSNL) Stock Analysis: A Promising 14.46% Upside Potential Amid Strategic Collaboration - DirectorsTalk Interviews
Aug Closing: Is Personalis Inc a defensive stockMarket Volume Report & Technical Pattern Recognition Alerts - baoquankhu1.vn
Aug Technicals: Is Personalis Inc showing insider buyingRate Cut & Reliable Momentum Entry Alerts - baoquankhu1.vn
cathie wood’s ARK stock trades highlight intellia, personalis buys By Investing.com - Investing.com Nigeria
cathie wood’s ARK stock trades highlight intellia, personalis buys - Investing.com
Personalis Stock Pre-Market (-4.0%): Downgrade Cites Competitive Headwinds - Trefis
Stop Loss: Can Personalis Inc stock double in the next yearTreasury Yields & Verified Swing Trading Watchlists - baoquankhu1.vn
Can Personalis Inc stock double in the next yearTrade Analysis Summary & Scalable Portfolio Growth Methods - baoquankhu1.vn
Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™ - FinancialContent
Risk Hedge: Is Personalis Inc benefiting from interest rate changesWeekly Market Outlook & Free Accurate Trade Setup Notifications - baoquankhu1.vn
Personalis, Inc. Announces Early Access Launch of Real-Time Variant Tracker - marketscreener.com
Personalis Reports Q3 2025 Financial Results - MSN
Will Personalis Inc. (04X) stock split increase liquidityWeekly Loss Report & Free Accurate Trade Setup Notifications - ulpravda.ru
Personalis (NASDAQ:PSNL) Given “Buy” Rating at BTIG Research - Defense World
Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates - sharewise.com
BTIG Reiterates Buy Rating for Personalis (PSNL) with $12 Target - GuruFocus
BTIG Research Reaffirms Buy Rating for Personalis (NASDAQ:PSNL) - MarketBeat
Is Personalis Inc. stock attractive for long term wealth building2025 Historical Comparison & Expert Curated Trade Setups - Улправда
Why Personalis Inc. stock remains a top recommendationJuly 2025 Market Mood & Risk Controlled Stock Alerts - Улправда
Is Personalis Inc. stock attractive for hedge fundsEarnings Recap Summary & Consistent Return Strategy Ideas - ulpravda.ru
Personalis (PSNL) Achieves Remarkable Growth in Clinical Volumes - GuruFocus
Can Personalis Inc. stock outperform in 2025 bull marketGap Down & Real-Time Buy Zone Alerts - ulpravda.ru
Is Personalis Inc. stock a buy for dividend growth2025 Macro Impact & Real-Time Chart Breakout Alerts - Улправда
Will Personalis Inc. stock remain a Wall Street favoriteQuarterly Portfolio Report & Risk Adjusted Swing Trade Ideas - Улправда
The $537B Precision Pivot: Why Molecular Monitoring is the New Oncology Standard - The Globe and Mail
Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights - BioSpace
PSNL Achieves Key Medicare Coverage Milestone for Breast Cancer - GuruFocus
Finanzdaten der Personalis Inc-Aktie (PSNL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.19%
0.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):